Corticosteroid therapy alone for the treatment of C3 glomerulonephritis in association with monoclonal gammopathy

Ladan Zand, Samih H. Nasr, Nelson Leung, Insara Jaffer Sathick

Research output: Contribution to journalArticle

Abstract

Introduction: C3 glomerulonephritis (C3GN) is a form of proliferative glomerulonephritis characterized by dominant glomerular C3 deposition. There is currently no consensus guideline on therapy for this disease. Experience with corticosteroids alone is scant in C3GN. We report the experience of treating patients with C3GN in association with monoclonal gammopathy with corticosteroid at a single center. Materials and methods: Corticosteroid therapy alone was used to treat 6 patients with C3GN who were also found to have monoclonal gammopathy at the time of presentation. Results: Median age of this cohort was 65 years. Median estimated glomerular filtration rate (eGFR) by MDRD equation was 31.6 mL/min/1.73m2 at presentation. After a median duration of follow-up of 23.5 months, all patients showed improvement in proteinuria: median proteinuria reduced from 2.3 to 0.5 g/d. Four of 6 patients showed improvement in kidney function. One patient who had required renal replacement therapy recovered renal function. Median eGFR at follow-up was 38.7 mL/min/1.73m2. Discussion: In patients with C3GN in association with monoclonal gammopathy, corticosteroid therapy alone may be a viable treatment option. Work-up should be done to exclude a hematologic neoplasm and inherited complement abnormalities before proceeding to corticosteroid therapy.

Original languageEnglish (US)
Pages (from-to)79-86
Number of pages8
JournalClinical nephrology
Volume91
Issue number2
DOIs
StatePublished - Feb 1 2019
Externally publishedYes

Fingerprint

Paraproteinemias
Glomerulonephritis
Adrenal Cortex Hormones
Glomerular Filtration Rate
Proteinuria
Therapeutics
Kidney
Renal Replacement Therapy
Hematologic Neoplasms
Guidelines

Keywords

  • C3 glomerulonephritis
  • Corticosteroid
  • Monoclonal gammopathy

ASJC Scopus subject areas

  • Nephrology

Cite this

Corticosteroid therapy alone for the treatment of C3 glomerulonephritis in association with monoclonal gammopathy. / Zand, Ladan; Nasr, Samih H.; Leung, Nelson; Sathick, Insara Jaffer.

In: Clinical nephrology, Vol. 91, No. 2, 01.02.2019, p. 79-86.

Research output: Contribution to journalArticle

Zand, Ladan ; Nasr, Samih H. ; Leung, Nelson ; Sathick, Insara Jaffer. / Corticosteroid therapy alone for the treatment of C3 glomerulonephritis in association with monoclonal gammopathy. In: Clinical nephrology. 2019 ; Vol. 91, No. 2. pp. 79-86.
@article{7b73993a990542b4a28fe72341c15118,
title = "Corticosteroid therapy alone for the treatment of C3 glomerulonephritis in association with monoclonal gammopathy",
abstract = "Introduction: C3 glomerulonephritis (C3GN) is a form of proliferative glomerulonephritis characterized by dominant glomerular C3 deposition. There is currently no consensus guideline on therapy for this disease. Experience with corticosteroids alone is scant in C3GN. We report the experience of treating patients with C3GN in association with monoclonal gammopathy with corticosteroid at a single center. Materials and methods: Corticosteroid therapy alone was used to treat 6 patients with C3GN who were also found to have monoclonal gammopathy at the time of presentation. Results: Median age of this cohort was 65 years. Median estimated glomerular filtration rate (eGFR) by MDRD equation was 31.6 mL/min/1.73m2 at presentation. After a median duration of follow-up of 23.5 months, all patients showed improvement in proteinuria: median proteinuria reduced from 2.3 to 0.5 g/d. Four of 6 patients showed improvement in kidney function. One patient who had required renal replacement therapy recovered renal function. Median eGFR at follow-up was 38.7 mL/min/1.73m2. Discussion: In patients with C3GN in association with monoclonal gammopathy, corticosteroid therapy alone may be a viable treatment option. Work-up should be done to exclude a hematologic neoplasm and inherited complement abnormalities before proceeding to corticosteroid therapy.",
keywords = "C3 glomerulonephritis, Corticosteroid, Monoclonal gammopathy",
author = "Ladan Zand and Nasr, {Samih H.} and Nelson Leung and Sathick, {Insara Jaffer}",
year = "2019",
month = "2",
day = "1",
doi = "10.5414/CN109442",
language = "English (US)",
volume = "91",
pages = "79--86",
journal = "Clinical Nephrology",
issn = "0301-0430",
publisher = "Dustri-Verlag Dr. Karl Feistle",
number = "2",

}

TY - JOUR

T1 - Corticosteroid therapy alone for the treatment of C3 glomerulonephritis in association with monoclonal gammopathy

AU - Zand, Ladan

AU - Nasr, Samih H.

AU - Leung, Nelson

AU - Sathick, Insara Jaffer

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Introduction: C3 glomerulonephritis (C3GN) is a form of proliferative glomerulonephritis characterized by dominant glomerular C3 deposition. There is currently no consensus guideline on therapy for this disease. Experience with corticosteroids alone is scant in C3GN. We report the experience of treating patients with C3GN in association with monoclonal gammopathy with corticosteroid at a single center. Materials and methods: Corticosteroid therapy alone was used to treat 6 patients with C3GN who were also found to have monoclonal gammopathy at the time of presentation. Results: Median age of this cohort was 65 years. Median estimated glomerular filtration rate (eGFR) by MDRD equation was 31.6 mL/min/1.73m2 at presentation. After a median duration of follow-up of 23.5 months, all patients showed improvement in proteinuria: median proteinuria reduced from 2.3 to 0.5 g/d. Four of 6 patients showed improvement in kidney function. One patient who had required renal replacement therapy recovered renal function. Median eGFR at follow-up was 38.7 mL/min/1.73m2. Discussion: In patients with C3GN in association with monoclonal gammopathy, corticosteroid therapy alone may be a viable treatment option. Work-up should be done to exclude a hematologic neoplasm and inherited complement abnormalities before proceeding to corticosteroid therapy.

AB - Introduction: C3 glomerulonephritis (C3GN) is a form of proliferative glomerulonephritis characterized by dominant glomerular C3 deposition. There is currently no consensus guideline on therapy for this disease. Experience with corticosteroids alone is scant in C3GN. We report the experience of treating patients with C3GN in association with monoclonal gammopathy with corticosteroid at a single center. Materials and methods: Corticosteroid therapy alone was used to treat 6 patients with C3GN who were also found to have monoclonal gammopathy at the time of presentation. Results: Median age of this cohort was 65 years. Median estimated glomerular filtration rate (eGFR) by MDRD equation was 31.6 mL/min/1.73m2 at presentation. After a median duration of follow-up of 23.5 months, all patients showed improvement in proteinuria: median proteinuria reduced from 2.3 to 0.5 g/d. Four of 6 patients showed improvement in kidney function. One patient who had required renal replacement therapy recovered renal function. Median eGFR at follow-up was 38.7 mL/min/1.73m2. Discussion: In patients with C3GN in association with monoclonal gammopathy, corticosteroid therapy alone may be a viable treatment option. Work-up should be done to exclude a hematologic neoplasm and inherited complement abnormalities before proceeding to corticosteroid therapy.

KW - C3 glomerulonephritis

KW - Corticosteroid

KW - Monoclonal gammopathy

UR - http://www.scopus.com/inward/record.url?scp=85060157569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060157569&partnerID=8YFLogxK

U2 - 10.5414/CN109442

DO - 10.5414/CN109442

M3 - Article

C2 - 30474593

AN - SCOPUS:85060157569

VL - 91

SP - 79

EP - 86

JO - Clinical Nephrology

JF - Clinical Nephrology

SN - 0301-0430

IS - 2

ER -